Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride replenishes potassium stores; potassium is the major intracellular cation and is essential for nerve conduction, muscle contraction, and acid-base balance. Dextrose provides calories and sodium chloride supplies sodium and chloride ions to maintain electrolyte balance.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Intravenous electrolyte replenishment,Maintenance of fluid and electrolyte balance,Prevention and treatment of hypokalemia,Caloric supplementation
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
IV infusion: 1 L contains 20 m Eq K+, 50 g dextrose, and 77 m Eq Na+ and Cl- each. Adjust rate based on potassium deficit and serum potassium. Typical adult rate: 10-20 m Eq/hour via peripheral IV, not to exceed 40 m Eq/hour or 200 m Eq/day.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Potassium: not applicable (homeostatic regulation); dextrose and sodium: endogenous, no elimination half-life. For exogenous potassium, distribution half-life ~1-1.5 h.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Potassium is primarily excreted renally; dextrose undergoes glycolysis and oxidative metabolism; sodium chloride is renally excreted.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal excretion: >90% of potassium is eliminated via kidneys; <10% fecal. Dextrose and sodium are primarily metabolized or renally excreted.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Potassium: essentially zero; dextrose: not bound; sodium: negligible binding.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Potassium: ~0.5 L/kg (body weight), representing total body water; sodium: ~0.2 L/kg (extracellular fluid); dextrose: ~0.2 L/kg (extracellular fluid).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100%; oral: 100% (for potassium, if no malabsorption; dextrose and sodium fully absorbed).
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
GFR >50 m L/min: no adjustment. GFR 30-50: reduce rate by 50% or use with caution. GFR 10-29: avoid use or give with extreme caution, monitor ECG and serum K+. GFR <10: contraindicated.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Child-Pugh A: no adjustment. Child-Pugh B: use with caution, monitor serum K+ closely. Child-Pugh C: contraindicated due to risk of hyperkalemia.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
IV infusion: 0.5-1 m Eq/kg/dose, max 20 m Eq per dose, given over 1-2 hours. Alternatively, 0.1-0.2 m Eq/kg/hour. Max infusion rate: 0.5 m Eq/kg/hour. Dextrose concentration should be monitored to avoid hypoglycemia.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Start at lower infusion rates (10-15 m Eq/hour) due to reduced renal function. Monitor serum potassium and renal function frequently. Consider maximum daily dose of 100 m Eq.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Concentrated potassium solutions (e.g., >40 m Eq/L) are for intravenous use only and must be diluted and administered slowly to avoid fatal hyperkalemia or cardiac arrest. Do not administer undiluted.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Monitor serum potassium levels frequently; risk of hyperkalemia especially in renal impairment or with potassium-sparing diuretics.,Avoid rapid infusion to prevent hyperkalemia-induced cardiac arrhythmias.,Use with caution in patients with heart failure, severe renal insufficiency, or conditions predisposing to hyperkalemia.,Intravenous administration may cause phlebitis or extravasation injury.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperkalemia,Severe renal failure with oliguria or anuria,Addison's disease (untreated),Adynamia episodica hereditaria (hyperkalemic periodic paralysis),Concomitant use of potassium-sparing diuretics (e.g., spironolactone, amiloride),Acute dehydration or heat cramps
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados) and potassium-containing salt substitutes, as this may increase risk of hyperkalemia.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Potassium chloride and dextrose are pregnancy category C. No adequate studies in pregnant women. Potassium chloride at therapeutic doses is unlikely to cause fetal harm. Dextrose is a normal constituent of fetal blood. Sodium chloride at physiologic concentrations is safe. However, maternal electrolyte imbalances could affect fetal homeostasis. First trimester: Theoretical risk of teratogenicity from electrolyte disturbances but no evidence with IV infusion. Second/third trimester: Risk of neonatal hypoglycemia or electrolyte abnormalities if maternal levels are abnormal. Use only if clearly needed.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Potassium and chloride are normal milk constituents; dextrose is also present. Infusion of these substances at therapeutic levels does not increase milk concentrations significantly. No specific M/P ratio available; considered compatible with breastfeeding. However, monitor infant for gastrointestinal effects if high doses given.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy induces increased plasma volume and renal blood flow, potentially increasing clearance of electrolytes. However, dosing of potassium chloride and sodium chloride should be based on serum levels and clinical need, not standard adjustments. Volume expansion in pregnancy may require higher infusion rates to achieve desired electrolyte correction. Monitor serum levels closely to avoid under- or over-correction.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Use with caution in patients with renal impairment, heart failure, or adrenal insufficiency due to risk of hyperkalemia. Monitor serum potassium levels regularly during infusion. Avoid use in patients with hyperkalemia or severe metabolic acidosis. This solution is isotonic and provides maintenance electrolytes and calories; adjust rate based on fluid and electrolyte status. Incompatible with amphotericin B, cefepime, and sodium bicarbonate in solution.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Inform your healthcare provider if you have kidney problems, heart disease, or are taking potassium-sparing diuretics or ACE inhibitors.,Report any symptoms of high potassium such as muscle weakness, numbness, tingling, or irregular heartbeat.,This medication is given intravenously; do not adjust the infusion rate yourself.,Avoid potassium-containing salt substitutes or potassium supplements unless directed by your doctor.,Inform your provider if you are pregnant or breastfeeding.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride replenishes potassium stores; potassium is the major intracellular cation and is essential for nerve conduction, muscle contraction, and acid-base balance. Dextrose provides calories and sodium chloride supplies sodium and chloride ions to maintain electrolyte balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is: IV infusion: 1 L contains 20 m Eq K+, 50 g dextrose, and 77 m Eq Na+ and Cl- each. Adjust rate based on potassium deficit and serum potassium. Typical adult rate: 10-20 m Eq/hour via peripheral IV, not to exceed 40 m Eq/hour or 200 m Eq/day.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride and dextrose are pregnancy category C. No adequate studies in pregnant women. Potassium chloride at therapeutic doses is unlikely to cause fetal harm. Dextrose i. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.